Vedanta Biosciences reveals Phase 2 VE303 results
27th January 2025 Uncategorised 0Study highlights VE303’s potential in reducing recurrent CDI More: Vedanta Biosciences reveals Phase 2 VE303 results Source: News
read more
Study highlights VE303’s potential in reducing recurrent CDI More: Vedanta Biosciences reveals Phase 2 VE303 results Source: News
read more
Comparison shows improved survival rates for pancreatic cancer treatment More: Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX Source: News
read moreModerna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare professionals and problems with the disclosure of transfers of value, respectively.
read moreNot long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a new commercial leader. More: Gearing
read morePfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.7 million to resolve kickback allegations tied to its neuroscience subsidiary’s migraine med Nurtec. More: Pfizer shells out nearly M to resolve Nurtec kickback claims inherited in Biohaven buyout
read moreOld drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients. More: Bristol Myers, Pfizer tout new standards of care in colorectal cancer
read more© 1994 - 2026 B.M. Pharmaceuticals